Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,164

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
ARTPre-Eclampsia
Interventions
DRUG

Aspirin

Experimental drug administrated orally

DRUG

Placebo

Treatment for the control group

Trial Locations (21)

Unknown

RECRUITING

CHU Angers, Angers

RECRUITING

CHU Bordeaux, Bordeaux

RECRUITING

CHU Clermont-Ferrand, Clermont-Ferrand

RECRUITING

CHU Dijon-Bourgogne, Dijon

RECRUITING

CHU Lille, Lille

RECRUITING

HCL - Groupement Hospitalier Est, Hôpital Femme Mère Enfant, Lyon

RECRUITING

AP-HM Hôpital de la Conception, Marseille

RECRUITING

AP-HM Hôpital Nord, Marseille

RECRUITING

CHU Montpellier, Montpellier

RECRUITING

CHRU Nancy, Nancy

RECRUITING

CHU Nantes, Nantes

RECRUITING

CHU Nîmes, Nîmes

RECRUITING

Groupe hospitalier St Joseph, Paris

NOT_YET_RECRUITING

Hôpital Armand - Trousseau, Paris

RECRUITING

Hôpital Cochin, Paris

RECRUITING

CHI Poissy Saint Germain en Laye, Poissy

NOT_YET_RECRUITING

CHU Poitiers, Poitiers

RECRUITING

CHU Rennes, Rennes

RECRUITING

CHU Saint Etienne, Hôpital Nord, Saint-Etienne

RECRUITING

CHU Strasbourg, Strasbourg

RECRUITING

CHU Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER